“Based on this evidence, D’OXYVA®, the first biotech solution of its kind to improve overall oxygen-rich blood flow, is perfectly suited to help improve health outcomes of COVID-19 patients, whether or not they have preexisting conditions.”

PASADENA, Calif. (PRWEB)
May 22, 2020

D’OXYVA® is a groundbreaking, completely painless, and noninvasive transdermal delivery system shown to improve blood perfusion and tissue oxygenation. A proprietary product of Circularity Healthcare, a private company focused on manufacturing medical technological products, D’OXYVA® could help reduce the impact of preexisting health conditions on the outcome of a COVID-19 infection.

People with an increased risk for COVID-19 infection are mainly those with previous health problems, such as cardiovascular disease, diabetes, respiratory disease, old age, and/or immunodeficiency. Among those risk factors, cardiovascular disease stands as one of the most dangerous. Even though the full extent of the interplay between cardiovascular disease and COVID-19 is not yet known, a recently discovered effect of a COVID-19 infection is the development of potentially deadly blood clots. By increasing tissue oxygenation through improved oxygen-rich blood flow, the health risk associated with preexisting cardiovascular disease can be countered by diminishing the effects of blood clotting and reducing the physical heart exertion needed to pump blood to major organs.

So far, acute treatment of serious cases of COVID-19 has involved using blood thinners (anticoagulants), like heparin, and oxygenation. D’OXYVA® represents a new treatment option.

D’OXYVA® uses vaporized, ultra-purified carbon dioxide to improve the body’s self-healing functions. It delivers this non-toxic compound via a non-invasive skin-delivery method, which has been shown to be more effective and safer than inhalation, a routine delivery method in hospital settings. The FDA-approved medical CO2 gets mixed with water inside the device, producing an active solution of supersaturated CO2 and water (H2O) vapor that improves skin microcirculation and blood circulation after dissolving into the skin.

Clinical studies have shown that D’OXYVA® increases O₂ saturation in patients treated with transdermal CO₂, in comparison to controls up to two hours after application; lowers heart rate; and increases perfusion index.

Based on this evidence, D’OXYVA®, the first biotech solution of its kind to improve overall oxygen-rich blood flow, is perfectly suited to help improve health outcomes of COVID-19 patients, whether or not they have preexisting conditions.

ABOUT CIRCULARITY HEALTHCARE

Circularity Healthcare, LLC, headquartered in Pasadena, California, is an emerging world leader in proprietary circulatory health and noninvasive delivery technologies, committed to helping improve life quality by developing, manufacturing, and marketing medical, pharmaceutical, and consumer health products. Circularity specializes in groundbreaking noninvasive technologies for affordable and portable transdermal delivery systems, and is pursuing regulatory approval worldwide as a way of handling cardiovascular and microcirculatory blood flow issues, as well as immune and autonomic nervous system disorders.

For more information, please visit http://www.circularityhealthcare.com or http://www.doxyva.com. Medical experts (Rx only) can visit http://www.doxyvaforwound.com to send general inquiries via the Contact Us page. For specific inquiries, contact Circularity Customer Care at info@doxyva.com info@circularityhealthcare.com or by phone toll free at 1-855-5DOXYVA or at 1-626-244-8090.

Forward-Looking Information

This press release may contain forward-looking information. This includes, or may be based upon, estimates, forecasts and statements as to management’s expectations with respect to, among other things, the quality of the products of Circularity Healthcare, LLC, its resources, progress in development, demand, and market outlook for non-invasive transdermal delivery medical devices. Forward-looking information is based on the opinions and estimates of management at the date the information is given and is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those initially projected. These factors include the inherent risks involved in the launch of a new medical device, innovation and market acceptance uncertainties, fluctuating components and other advanced material prices, new federal or state governmental regulations, the possibility of project cost overruns or unanticipated costs and expenses, uncertainties relating to the availability and costs of financing needed in the future and other factors. The forward-looking information contained herein is given as of the date hereof and Circularity Healthcare, LLC assumes no responsibility to update or revise such information to reflect new events or circumstances, except as required by law. Circularity Healthcare, LLC makes no representations or warranties as to the accuracy or completeness of this press release and shall have no liability for any representations (expressed or implied) for any statement made herein, or for any omission from this press release.

Share article on social media or email:

NEW YORK (PRWEB)
May 22, 2020

Global leaders in the research, manufacturing and purification of high-quality health ingredients, Kyowa Hakko USA took the initiative to provide support for NYC health care workers on the frontlines while also partnering with ingredient customer on a unique program.

Kyowa Hakko USA, whose headquarters are located in New York City, worked to raise funds and match a considerable donation for NYC Health + Hospitals, the largest public health care system in the nation with more than 42,000 employees on the frontlines caring for New Yorkers in Emergency Rooms, ICUs, community health centers and nursing homes. Donations contributed to meals, groceries, supplies, and transportation services to help support doctors, nurses and other health care workers throughout the COVID-19 pandemic.

“During this time of crisis and uncertainty, supporting our local NYC health care workers who are laboring tirelessly around the clock is of utmost priority for us,” comments Leo Cullen, President of Kyowa Hakko U.S.A. Inc., “At Kyowa Hakko, we strive to contribute to the optimal health and well-being of people around the world, and we hope our response efforts will help further this mission as we all grapple with this crisis,” he remarks.

Kyowa Hakko also made moves to partner with one of their customers to support an initiative dedicated to help fitness professionals, who have been hard-hit by nationwide shutdowns of gyms and training facilities, generate additional income throughout this trying time.

“Just as it’s imperative for us to support our health care workers, it’s also essential for us to support our customers with their COVID-19 response initiatives,” says Cullen “We hope that our efforts to help get this campaign started will foster a positive impact for our nation’s fitness professionals whose jobs have been deeply affected by COVID-19,” he adds, “When key players in the health and wellness industry can work together, real hope for optimism and change emerges. At Kyowa Hakko, we’re proud to be a part of that hope during this challenging time.”

Media interested in setting up an interview with a representative from Kyowa Hakko, please contact Sara White at sara@adinnyc.com or 914.621.1323.

About Kyowa Hakko USA:

Kyowa Hakko USA is the North & South American office for Kyowa Hakko Bio Co. Ltd., an international health ingredients manufacturer and world leader in the development,

manufacturing, and marketing of pharmaceuticals, nutraceuticals and food products. For more information visit Kyowa-USA.com.

Share article on social media or email:

Xtalks Life Science Webinars

While returning to the new normal of laboratory operations, best Asset Management practices can increase the efficiency of laboratory operations, saving time and money while ensuring that scientists can meet or exceed productivity goals by focusing on their science.

TORONTO (PRWEB)
May 22, 2020

As laboratory operations return to a “back to business” mode following temporary site closures and/or increased site schedule intensity surrounding recent world events, there are things that can be done to better support Asset Management processes and systems. This webinar will focus on advancing lab-wide operations by promoting visibility and simplification while optimizing operational and economical outcomes. Agilent experts will guide participants through restarting lab operations with asset management best practices.

The field of healthcare has been especially affected by current global events. Scientific research, manufacturing, and testing facilities are no exceptions. With public health in the spotlight, these and other industries are responding to unique challenges while facing reduced facility access, site closures, working from home, social distancing and irregular schedules. With safety top of mind, throughput and capacity planning require additional strategy review. Getting to market faster and more efficiently has immediate impact beyond the bottom line.

This webinar will address ways to refocus learnings from times of shut down and round the clock intensity to operate more efficiently to support the needs of patients, employees and society. While returning to the new normal of laboratory operations, best Asset Management practices can increase the efficiency of laboratory operations, saving time and money while ensuring that scientists can meet or exceed productivity goals by focusing on their science.

As operations are prepared for “back to business” following the temporary site closures and/or increased site schedule intensity surrounding current world events, there are things we can do to better support our Asset Management processes and systems.

Join this webinar to learn how to simplify operations, extract more value from existing assets and expand opportunities.

Join Melissa Zeier, Lab Productivity Application Expert, Agilent in a live webinar on Wednesday, June 10, 2020 at 2pm EDT.

For more information or to register for this event, visit Back to Laboratory Productivity in the New Normal: Optimizing Operations through Asset Management.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email:

“We are confident that our unique solution can save millions of lives of those with chronic illnesses in the fight against COVID-19.”

PASADENA, Calif. (PRWEB)
May 22, 2020

An emerging biotech leader with operations in over three dozen countries, Circularity Healthcare, in partnership with Watson Wellness Center in Oakland, California, announce the launch of a new clinical trial aimed at treating the main underlying medical conditions related to the most severe COVID-19 cases. Led by Oakland-based H. Geoffrey Watson, M.D., the clinic recently became a COVID-19 testing site and is in the process of becoming a by-appointment testing center for Alameda County.

This groundbreaking clinical trial will feature the administration of Circularity’s latest patented and patent-pending, noninvasive and painless, ultra-portable, transdermal (over the skin) drug delivery device D’OXYVA® (deoxyhemoglobin vasodilator). D’OXYVA has consistently demonstrated success over eight years of involvement in dozens of human studies and has received user feedback from thousands of people in dozens of countries where other drugs and treatment options have failed. D’OXYVA directly addresses the issue of low-oxygen blood flow, which is especially important for at-risk COVID-19 patients.

D’OXYVA® is the first noninvasive solution of its kind to elegantly achieve major skin, tissue, and vascular blood flow improvement (often 300 percent from baseline) in the microcirculation — a painless process that has been proven to significantly increase overall oxygen-rich blood flow throughout the body and boost new vessel structure growth (angiogenesis). This widely studied process has been applied to the treatment of a variety of conditions related to low oxygen in the blood, including diabetes, sepsis, septic shock, hypertension, cardiovascular complications, COPD, and high blood pressure, which are common underlying conditions in the most vulnerable COVID-19 patients. According to a study in the Journal of the American Medical Association, nearly all patients hospitalized with COVID-19 at the epicenter in New York City had chronic health issues, and most — 88 percent — had at least two, including high blood pressure, diabetes, heart disease, kidney disease, obesity, and chronic respiratory illnesses.

“We are thrilled to partner with such a distinguished expert as Dr. Geoffrey Watson in this groundbreaking COVID-19 clinical trial,” says Circularity Healthcare president and CEO Norbert Kiss. “We are confident that our unique solution can save millions of lives of those with chronic illnesses in the fight against COVID-19.”

D’OXYVA works by utilizing FDA-approved, pharmaceutical-grade, ultra-purified carbon dioxide (gasotransmitter) currently used by doctors, clinics, and hospitals worldwide. This nontoxic, simple medical gas molecule is delivered through the skin by D’OXYVA’s rapid delivery system, and induces vasodilation and vasoconstriction, leading to increased perfusion and, ultimately, healing. More than eight years of clinical evidence collection involving D’OXYVA has demonstrated significantly reduced inflammation and fever in patients, in addition to reinforcing the immune system and improving white blood cell production, oxygen-rich blood circulation, toxic waste removal, and a host of inflammatory markers. These improvements are combined with powerful additional hormonal and neural functions that benefit nearly all patients, young and old, men and women, from all ethnic backgrounds.

A big part of the science behind D’OXYVA® are the 2019 Nobel Prize in Physiology or Medicine-winning findings that showed how oxygen levels affect cellular metabolism and physiological function, paving the way for oxygen to be used as a promising new method to fight many diseases, including various types of cancer. Another of Circularity’s IRB-approved human clinical trials is expanding into Phase 3 and centers on healing diabetic foot ulcers at one-tenth of the time and current healthcare costs.

“We couldn’t be more pleased to be able to offer this treatment option to those most in need, and especially to the African American community, which has been shown to be disproportionately affected by the crisis caused by the novel coronavirus and underlying medical conditions,” says Circularity’s national vice president of sales Larry Kimble.

In addition, D’OXYVA is currently available over the counter for at-home use. The easy-to-use, fully mechanical, hand-held device requires no electricity or special training, and is intended to ease the expense and inconvenience of time-consuming doctor visits by offering relatively affordable and effective management of mild to severe health conditions in the comfort of your own home or on-the-go.

The company is also actively accepting donation requests from nurses and doctors to provide D’OXYVA for immediate lifesaving treatment of hospital patients in critical condition, or those diagnosed with COVID-19, due to its Investigational Device Exemption (IDE) status under FDA regulations. Physicians and potential patients interested in participating in Circularity’s COVID-19 clinical trial at home or for in-hospital use can visit https://doxyva.com/covid-19/ or call (626) 817-6698 for more information.

About Circularity Healthcare, LLC

Headquartered in Pasadena, California, Circularity Healthcare is an emerging biotech leader around the world in proprietary circulatory health and noninvasive skin delivery technologies. Since 2011, the company has been committed to radically changing the standard of care and improving lives by developing, manufacturing, and marketing affordable medical devices and pharmaceutical products to promote consumer health and wellness. For more information, please visit https://doxyva.com.

About Dr. Geoffrey Watson

Dr. Geoffrey Watson holds a B.S. in health care administration from the University of California at Davis and a medical degree from Vanderbilt University in Nashville, Tennessee. Dr. Watson completed two years of his medical residency at the Vanderbilt Medical Center, with his final year of medical residency completed at the University of California Medical Center in San Francisco. Dr. Watson has become a significant voice in educating the community who focuses his message through the media on healing the community via positive preventive pathways. His devotion has been recognized by the Bay Area community and he has served as the primary physician for the afternoon news on KRON-TV in San Francisco.

Forward-Looking Information

This press release may contain forward-looking information. This includes, or may be based upon, estimates, forecasts and statements as to management’s expectations with respect to, among other things, the quality of the products of Circularity Healthcare, LLC, its resources, progress in development, demand, and market outlook for non-invasive transdermal delivery medical devices. Forward-looking information is based on the opinions and estimates of management at the date the information is given and is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those initially projected. These factors include the inherent risks involved in the launch of a new medical device, innovation and market acceptance uncertainties, fluctuating components and other advanced material prices, new federal or state governmental regulations, the possibility of project cost overruns or unanticipated costs and expenses, uncertainties relating to the availability and costs of financing needed in the future and other factors. The forward-looking information contained herein is given as of the date hereof and Circularity Healthcare, LLC assumes no responsibility to update or revise such information to reflect new events or circumstances, except as required by law. Circularity Healthcare, LLC makes no representations or warranties as to the accuracy or completeness of this press release and shall have no liability for any representations (expressed or implied) for any statement made herein, or for any omission from this press release.

Connect with D’OXYVA on Social Media:

https://twitter.com/doxyvahealth

https://www.facebook.com/DOxyva

https://www.instagram.com/doxyva_health/

https://www.youtube.com/c/circularitydoxyvas

For media inquiries, please contact:

Melissa Edwards

melissa@dunnpelliermedia.com

(323) 481-2307

PetDesk Video Chat powered by Twilio

“Video Chat has enabled us to connect with clients in the exam room while we are working with curbside only appointments. Nothing can replace the personal interaction, but having them see and hear us in real time has been a game changer,” said Elizabeth Chapman DVM, owner Just Cats Clinic.

SAN DIEGO (PRWEB)
May 22, 2020

PetDesk is making its telemedicine technology, live Video Chat powered by Twilio, available to all customers free for three months thanks to Twilio’s Video Boost Program. Launched in early April to PetDesk customers through a beta program, integrated Video Chat has been able to provide flexibility during a time when veterinary clients stay at home and clinics accommodate innovative ways to extend access to care.    

“The past six weeks have proven our telemedicine technology allows clinics customization and the flexibility to securely connect with their clients no matter where they are each located. We accelerated the launch of Video Chat to help customers during this critical time and the Video Boost Program makes the technology even more accessible with three free months of service,” said Taylor Cavanah, CEO of PetDesk. “We are thrilled that Twilio’s program dedicated to supporting healthcare, education and non-profit sectors during COVID-19 includes the essential work of veterinarians.”

With secure Video Chat integrated into the PetDesk platform, clinics now have a secure option for both synchronous and asynchronous communication. With everything contained in a single dashboard, it makes it easy for staff to manage workflows, including scheduling appointments. PetDesk’s Virtual Care options, Two-Way Messaging and Video Chat, allow customers to choose what is best for their patient and client. With the average American spending 5.7 hours a day on their phone and many millennials spending an average of 58 minutes a day texting, clients are already using a convenient communication option that will allow you to connect with them – their cellphone. Being able to launch a Video Chat right from the PetDesk Mobile Health App provides an easy experience for the client and a seamless process for the clinic. Rapid adoption of PetDesk’s Two-Way Messaging continues and today three times as many customers are using Two-Way and messages sent per clinic are up 100% vs. prior to the COVID-19 pandemic.

Since the beta program started a few weeks ago, clinics have been using secure Video Chat to continue delivering top-notch care while meeting social distancing guidelines from the CDC and AVMA. Average appointment times are 26 minutes and use cases during the COVID-19 pandemic have included: doctors working from home, curbside appointments while allowing clients to watch the patient’s in-clinic exam, and pets being evaluated from the comfort of their home to keep high-risk pet parents safe. “Video Chat has enabled us to connect with clients in the exam room while we are working with curbside only appointments. Nothing can replace the personal interaction, but having them see and hear us in real time has been a game changer,” said Elizabeth Chapman DVM, owner Just Cats Clinic.

PetDesk customers can easily implement Video Chat thanks to PetDesk’s customized onboarding and training services. Learn more at petdesk.com. For free resources about implementing veterinary telemedicine tools and offer details, visit the PetDesk blog.

About PetDesk

PetDesk, an industry leader in veterinary client communication software, has helped over 2,100 veterinary practices streamline business with simple software solutions that help pet parents stay current and pet care providers stay connected. The PetDesk Experience has garnered more than 1.5 million app users and a 5-Star Capterra rating by offering powerful features including a 5-Star Rated Pet Health Mobile App and industry-leading customer support. The 100,000 reviews across the App and Google Play Stores are evidence of PetDesk’s commitment to connecting pet owners to pet care providers. Founded in 2013, PetDesk secured a Series-B Investment of $12 million from Silicon Valley-based PeakSpan Capital in December 2018. Headquartered in San Diego, PetDesk has more than 70 employees and proudly supports a gender-balanced and pet-friendly workforce. For more information about PetDesk, visit ​http://www.petdesk.com.

Share article on social media or email:

Shady Grove Fertility Atlanta Physician, Desireé McCarthy-Keith, M.D., Honored as 2020 Top Doctor, Georgia Trend Magazine.

It’s a true honor to be recognized among so many other highly esteemed physicians throughout our state. I’m not only proud but grateful to be recognized in the community for the work we do as a team to help build families.

ATLANTA (PRWEB)
May 22, 2020

SGF Atlanta is proud to announce that its Medical Director, award-winning physician, Desireé McCarthy-Keith, M.D., has been named a Georgia Trend Magazine Top Doctor 2020 for Reproductive Endocrinology and Infertility (REI).

The inaugural top doctors list of the state’s top physicians represent 56 specialties from addiction medicine to vascular surgery – and can be found throughout Georgia, from Gainesville to Dublin, Metro Atlanta to Macon, and Thomasville to Brunswick.

The list was created in partnership with DataJoe Research, who facilitated a peer-voting process followed by referencing government sources to ensure each nominated physician was in good standing with regards to current, active license status with the state regulatory board.

“It’s a true honor to be recognized among so many other highly esteemed physicians throughout our state. I’m not only proud but grateful to be recognized in the community for the work we do as a team to help build families,” said.

Dr. McCarthy-Keith, who sees patients in SGF’s Atlanta-Northside and Alpharetta locations was named Medical Director of SGF Atlanta in February 2019, providing clinical leadership, overseeing quality assurance, and supporting efforts to maintain the Atlanta practice’s IVF Center of Excellence status in REI.

As a leader in the field of infertility, Dr. McCarthy-Keith’s medical expertise and reputation have garnered her significant press coverage by top media outlets and publications, such as Oprah Magazine, Women’s Health, Today.com, and NPR. Dr. McCarthy-Keith was also named a Top Doc for Infertility by Atlanta Magazine, a recipient of Best Fertility Specialist in Atlanta by Kudzu, Black Health Magazine’s Most Influential African-American Doctors, Who’s Who in Black Atlanta (2011, 2012, 2014-2018), and Mom-Approved Fertility Specialist in Atlanta Parent Magazine.

SGF Atlanta—home to Dr. McCarthy-Keith and fellow physicians, Drs. Anne Namnoum, Mark Perloe, and Pavna Brahma—has also earned numerous accolades in the region including Best Reproductive Endocrinology Practice by Kudzu—a distinction earned through a voting process by members of the surrounding Atlanta community.

SGF Atlanta has 4 locations, including Atlanta-Northside, Alpharetta, Marietta, and Buckhead-Piedmont.

To schedule an appointment with Dr. McCarthy-Keith or another SGF Atlanta physician, please call 888-761-1967 or complete this brief online form.

About Shady Grove Fertility (SGF)

SGF is a leading fertility and IVF center of excellence with more than 85,000 babies born and counting. With 38 locations throughout FL, GA, MD, NY, PA, VA, D.C., and Santiago, Chile, we offer patients virtual physician consults, individualized care, accept most insurance plans, and make treatment affordable through innovative financial options, including treatment guarantees. More physicians refer their patients to SGF than any other center. Call 1-888-761-1967 or visit ShadyGroveFertility.com.

Share article on social media or email: